Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Scientists create natural Alzheimer’s-fighting compound in lab

By Drug Discovery Trends Editor | August 25, 2011

Scientists
at Yale University have developed the first
practical method to create a compound called huperzine A in the laboratory. The
compound, which occurs naturally in a species of moss found in China, is an enzyme inhibitor that has been used
to treat Alzheimer’s disease in China
since the late 1990s and is sold in the U.S. as a dietary supplement to
help maintain memory. Scientists believe it could also potentially combat the
effects of chemical warfare agents.

Until
now, researchers have only been able to derive small amounts of the compound
directly from the Huperzia serrata plant, or had to resort to lengthy
and cumbersome methods to synthesize it in the laboratory.

Now
researchers at Yale have developed a practical and cost-effective method to
synthesize huperzine A in the laboratory. The process requires just eight steps
and produces a yield of 40%. Previously, the best synthetic techniques had
required twice as many steps and achieved yields of only 2%.

“Being
able to synthesize large amounts of huperzine A in the laboratory is crucial
because the plant itself, which has been used in Chinese folk medicine for
centuries, takes decades to grow and is nearing extinction due to
overharvesting,” says Seth Herzon, the Yale chemist who led the research,
which is described in Chemical Science.

In
some places, huperzine A can cost up to $1,000 per milligram. Herzon and his
team produced several grams of the compound in their laboratory and are capable
of creating much more. They believe they will be able to drive the cost down to
just 50 cents per milligram, and have partnered with an industrial firm to help
produce it on larger scales.

The
firm plans to comprehensively evaluate the therapeutic potential of huperzine A
by conducting clinical trials for several different neurological disorders in
the U.S.
In addition, the Herzon laboratory and the firm are working with the U.S. Army,
which is interested in huperzine A’s potential in blocking the effects of chemical
warfare agents, he says. The compound has been shown to protect primates
against chemical warfare agents, without side effects.

Other
Alzheimer’s treatments based on enzyme inhibitors are currently prescribed in
the U.S.,
but huperzine A binds better, is more easily absorbed by the body and last
longer in the body than other treatments, Herzon says.

“We believe huperzine A has the potential to
treat a range of neurologic disorders more effectively than the current options
available,” Herzon says. “And we now have a route to huperzine A that
rivals nature’s pathway.”

SOURCE


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE